RevBio Receives a $2 Million NIH Grant to Pursue the Treatment of Wrist Fractures with Its Innovative Bone Adhesive Technology

RevBio, Inc., announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant expected to total $2 million over two years from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of wrist fractures with its patented bone adhesive technology known as Tetranite®. Read more >>